Novel technology for anticancer drug delivery on demand
With the goal of minimizing the side effects of chemotherapy on healthy tissues, a team of researchers at the Center for Self-assembly and Complexity, within the Institute for Basic Science (IBS) have developed novel nanocontainers able to deliver anticancer drugs at precise timing and location. The study combines uniquely designed molecules and light-dependent drug release, which may provide a new platform to enhance the effect of anticancer therapeutics.
Hollow pumpkin-shaped molecules with allyloxy tails self-assemble into vesicles which can carry drugs into cancer cells. Then a laser breaks the vesicles which facilitates the release of the drug in a timely and location-specific manner.
IBS
A) and B) show the chemical structure of the AO1CB[7] molecule. C) After vigorous shaking of AO1CB[7] in water, the solution becomes cloudy and foam forms on top, meaning that AO1CB[7] behaves like a surfactant.
IBS
The chemotherapeutic drug Doxorubicin (Dox, in red) was entrapped in AO1CB[7] vesicles and delivered to cervical cancer cells (HeLa cells). The image compares the location of Dox in the absence A) and presence B) of infra-red two-photon laser irradiation. In B) the drug is visible inside the nucleus (stained in blue), meaning that the vesicles were disrupted and the drug was able to reach the nucleus, where it fights the cancerous tumor with increased efficiency.
IBS
Thanks to a serendipitous observation, IBS researchers at POSTECH found out that tailed pumpkin-shaped molecules, mono-allyloxylated cucurbit[7]uril (AO1CB[7]), act as surfactant in water. Most surfactants, like soap molecules in bubbles and phospholipids in cellular membranes, have small water-loving (hydrophilic) heads and long fat-loving (hydrophobic) tails that determine how they arrange in space. In contrast, AO1CB[7] is rather unconventional as it forms vesicles in water despite its short hydrophobic allyloxy tail. Detailed analysis showed that the tails unite AO1CB[7] molecules into colloidal particles.
"Seeing AO1CB[7] forming a cloudy solution when shaken in water was an unexpected surprise for the team," explains PARK Kyeng Min, the first and corresponding author of the study. "We thought to take advantage of this newly discovered property and use these vesicles as vehicles to carry anticancer drugs. Then, by controlling when and where the vesicles are broken, the drugs could be released on demand."
Beyond helping AO1CB[7] to self-assemble, the allyloxy tail is also light-responsive: it can react with molecules such as glutathione normally present in cells when irradiated by UV light (365 nanometer wavelength). Similarly to a soap bubble popping, the reaction between the tails and glutathione molecules breaks the AO1CB[7] vesicles apart.
Rather than using UV single-photon laser to promote the glutathione-allyloxy tail reaction, IBS researchers employed a near infrared two-photon laser, which has the ability to penetrate deeper into tissues with increased accuracy. In simple terms, the two-photon laser (wavelength 720 nanometers) is a better tool to use than a single-photon laser (365 nanometers) as it can reach deeper inside flesh with less scattering. As the irradiated area is smaller, the drug delivery is confined to the targeted area, resulting in less damage to healthy tissue surrounding the tumor.
The research team applied this technology to deliver the chemotherapeutic drug Doxorubicin to cervical cancer cells (HeLa cells) in the laboratory. They observed that the drug was able to exit the vesicles, reach the nucleus of the cancer cells, and eventually kill them.
"These cell-level studies represent a proof-of-concept demonstration. Now we want to extend this technology to animal models, such as cancer bearing mice, to verify its practical use in different types of tumors," explains Park.
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
